Pipeline Companies

LyGenesis


A spinout from University of Pittsburgh’s McGowan Institute for Regenerative Medicine, Lygenesis’ technology will enable the use of a patient’s own lymph nodes as bioreactors to regrow functioning ectopic organs including liver, kidney, thymus, and pancreas.

The initial target for clinical development is liver regeneration, with a focus on helping patients with end-stage liver disease (ESLD) using a hepatocyte cell therapy product which is implanted into the periduodenal lymph nodes.  These hepatocytes engraft, vascularize, and perform all of the functions typical to liver tissue, enabling them to rescue patients from ESLD.

Lygenesis’ technology allows a single donated liver to act as the seed for dozens of transplants using outpatient endoscopy. Likely to be classified as a cell therapy, it represents a near-term example of regenerative medicine. In an example of the sort of cross-pollination Juvenescence encourages in its ecosystem, Lygenesis is exploring the use of cell-lines from AgeX in order to create off-the-shelf therapies that may eliminate the need for immunosuppression or donors.

There are no approved treatments for ESLD. Lygenesis’ technology could revolutionize the transplant market, allowing patients to avoid the requirement for liver transplant along with extending the lifespan of those unsuited to a liver transplant.

View Website

AgeX Therapeutics


AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

PureStem® is AgeX’s cell derivation and manufacturing platform and UniverCyte™ is its immune tolerance platform. They are designed to work together to generate highly-defined, hypoimmunogenic, allogeneic, off-the-shelf, low COGS, pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. 

induced Tissue Regeneration (iTR™) is AgeX’s revolutionary longevity platform which aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. 

HyStem is AgeX’s cell and small molecule delivery technology designed to stably engraft cell therapies or to slowly release iTR small molecules in the body for higher efficacy and safety.

AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.

View Website

FoxBio


FoxBio is a 50/50 joint venture between Juvenescence and Antoxerene, a subsidiary of growing discovery/pre-clinical CRO Ichor Therapeutics. The company is focused on developing small molecule senolytics targeting a major survival pathway relied on by senescent cells.

Cellular senescence is an irreversible arrest in cell proliferation that occurs in response to severe stresses, including telomere shortening, oncogene activation, DNA damage, and oxidative stress. Senescent cells remain metabolically active and secrete inflammatory molecules, termed the senescence-associated secretory phenotype (SASP), which are linked to many diseases of aging.

Ichor Therapeutics was founded by Kelsey Moody, former research scientist and founder of student research initiatives at Aubrey de Grey’s SENS Research Foundation.

Insilico Medicine


Insilico Medicine, Inc. is a Johns Hopkins-based company using artificial intelligence (AI) and deep learning for drug discovery to produce compounds targeted to the diseases of aging.

Juvenescence and Insilico have created a joint venture, Generait Pharmaceuticals, that has the first right to five compounds per year from Insilico.

Insilico Medicine’s “end-to-end” AI platform for drug discovery covers target identification & validation, compound generation, and patient selection. Insilico’s capabilities can be leveraged by the Juvenescence pipeline companies to speed hit-to-lead discovery.

View Website

Generait Pharmaceuticals


Generait is a drug development and artificial intelligence company with a specific mission of finding diagnostic and therapeutic agents to address aging, as well as age-related diseases. 

Previously Juvenescence AI limited, Generait was founded in July 2017, a partnership between Juvenescence and the leading AI drug discovery company Insilico Medicine, Inc, providing a vehicle to develop promising candidates identified using its end-to-end automated drug discovery pipeline through to clinical proof of concept.

The company combines advances in artificial intelligence with classical development expertise in order to prioritize and develop compounds from its AI/machine learning partnerships.

NetraPharma


NetraPharma is a 50/50 partnership between Juvenescence and NetraMark Corp, and is a clinical-development focused machine learning company. 

NetraPharma’s technology is a novel mathematical technique to integrate the outputs of multiple different machine learning algorithms, including gradient boosting, random forests, neural networks, GANs, quantum computation, and others. It enables the segmentation of subgroups within datasets when only a limited number of inputs are available. 

The system is particularly adept at identifying placebo responders and non-responders, and with patient reported outcome measures (PROMs), lending itself to psychiatric diseases, where initial validation data has demonstrated viability. NetraPharma plans to use this technology to help companies with failed clinical trials identify overlooked subpopulations of responding patients.  

Souvien Therapeutics


Souvien Therapeutics is a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Stephen Haggarty, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital.

The development plan is based on a substantial body of data implicating a critical epigenetic regulator of cellular ageing in neurodegeneration.

BYOMass


BYOMass is a Massachusetts-based company, focused on developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.

Aging drives the chronic diseases that are the biggest burden on the medical system, and BYOMass has built a compelling case around modulating defined targets to alleviate multi-morbidity.

BHB Therapeutics


BHB Therapeutics is a joint venture between Juvenescence and the Buck Institute for Research on Aging. The company will focus on novel approaches to inducing a state of ketosis, which may have protective effects against age-related disease. The work is based on the research in the labs of Eric Verdin, MD and John Newman, MD, PhD.

The work centers on the emerging signalling functions of a metabolite created by the body during fasting or exercise, the ketone body beta-hydroxybutyrate (BHB). They have discovered that BHB helps the body respond to stresses, and that long-term exposure to ketone bodies using a ketogenic diet can extend healthy lifespan in model systems.

Napa Therapeutics


Napa Therapeutics is a spinout from the Buck Institute for Research on Aging, financed by Juvenescence.

It is a very important first step in Juvenescence’s model to create collaborations between basic scientists and drug developers.

Napa is a discovery-stage company focused on NAD+ metabolism. There is ample evidence that NAD+ depletion is a key feature of aging. Napa’s core IP will surround a novel target within NAD+ metabolism to increase levels of NAD+ within the tissue.

Napa has engaged Insilico Medicine to identify small molecule modulators of an undisclosed target highlighted in Dr. Eric Verdin’s research.